<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478580</url>
  </required_header>
  <id_info>
    <org_study_id>10-041</org_study_id>
    <nct_id>NCT02478580</nct_id>
  </id_info>
  <brief_title>Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients</brief_title>
  <official_title>The Effects of Armodafinil (Nuvigil) on Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) and obesity is associated with increased perioperative
      morbidity and mortality. This group of patients is at risk of perioperative desaturations
      which can be worsened by perioperative sedatives and narcotics needed for surgery. OSA
      patients might also need to spend the night in intensive care for more frequent monitoring
      for any desaturations episodes especially if the patient will be requiring multiple
      intravenous narcotic boluses for pain control. Several studies have looked into the most
      appropriate way to manage these patients and some recommendations have been made to avoid
      outpatient surgery with close monitoring for first 24 hours after surgery specifically if
      patient will require intravenous postoperative narcotics.

      Nuvigil (Armodafinil) is a wake promoting agent (Cephalon inc., West Chester, PA) that's FDA
      approved for excessive daytime sleepiness in narcolepsy, shift work sleep disorder, and
      obstructive sleep apnea. The precise mechanism(s) through which armodafinil (R-enantiomer) or
      modafinil (mixture of R- and S-enantiomers) promote wakefulness is unknown.

      Nuvigil is longer acting product which is similar in action to Modafinil however is much
      cheaper. Nuvigil has not been previously studied for postoperative recovery. The
      investigators intend to study the effects of Nuvigil on postoperative recovery time and
      wakefulness in obstructive sleep apnea and obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modafinil has been shown to improve recovery after general anesthesia in a small pilot study
      which involved 30 patients. In these study, patients were given one dose of Modafinil 200mg
      po versus placebo after surgery when patient tolerating po with a sip of water and were
      discharged home. They were asked to assess their fatigue, alertness and energy level during
      the following 24 hrs. Modafinil was found to significantly reduce fatigue and improves
      feelings of alertness and energy in postoperative patients. It was concluded that patients
      recovering from general anesthesia can significantly benefit from Modafinil.

      A more recent study looked at the perioperative use of Modafinil in 67 patients presenting
      for lithotripsy requiring sedation. Goal was to asses improvement in recovery compared to
      placebo. Patients were randomized to 4 groups 1 and 2 received midazolam/ fentanyl sedation
      plus Modafinil 200mg po given 1 hr before sedation versus placebo, the other two received
      remifentanil / propofol infusion plus Modafinil 20 mg po versus placebo. Groups were compared
      using the digital symbol substitution test (DSST), trail making test (TMT), observer scale of
      sedation and analgesia (OAA/S) and Aldrete score and they found no statistical significant
      difference between groups. However they measured the Verbal rating scale (VRS) scores for
      secondary outcome variables e.g. energy, tiredness and dizziness were also recorded before
      and after treatment. They concluded that Modafinil reduces patient-reported tiredness after
      sedation/analgesia however does not improve recovery in terms of objective measures of
      patient psychomotor skills.

      Nuvigil is longer acting product which is similar in action to Modafinil and has not been
      previously studied for postoperative recovery. We intend to study the effects of Nuvigil on
      postoperative recovery time and wakefulness in obstructive sleep apnea patients and obese
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Care Unit (PACU) Recovery Time</measure>
    <time_frame>Immediate postoperative period (up to 3 hours)</time_frame>
    <description>Participants will be followed for the duration of PACU stay, an expected average of 3 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Aldrete Score</measure>
    <time_frame>2 hours after extubation</time_frame>
    <description>Aldrete score used for readiness of PACU discharge by assigning numeric values to the criteria including activity, respiration, circulation, consciousness, and color. Each criterion is rated from 0 to 2, with a maximum score of 10. Scores in the range of 9 to 10 are considered satisfactory for PACU discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Obesity</condition>
  <condition>Premature Recovery From Anesthesia</condition>
  <arm_group>
    <arm_group_label>Nuvigil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of Nuvigil at 150mg dose in preoperative area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single oral placebo will be given in preoperative area</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nuvigil</intervention_name>
    <description>Patients will receive Nuvigil before the surgery</description>
    <arm_group_label>Nuvigil</arm_group_label>
    <other_name>Armodafinil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given before surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Oral placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient presented for surgery under general anesthesia

          -  Documented OSA

          -  Patients with BMI above 35

        Exclusion Criteria:

          -  Coronary Artery Disease or Myocardial infarcts

          -  Mitral valve prolapse

          -  Cyclosporine, contraceptive drugs

          -  Known allergic reaction to Modafinil or any of its products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enas Kandil</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>February 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2016</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Enas Kandil</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Anesthesia Recovery Period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nuvigil</title>
          <description>A single oral dose of Nuvigil 150mg in preoperative area
NUVIGIL: Patient will receive Nuvigil before the surgery</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Placebo in preoperative area
Patient will receive placebo before the surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patient with obstructive sleep apnea undergoing surgery</population>
      <group_list>
        <group group_id="B1">
          <title>Nuvigil</title>
          <description>A single oral dose of Nuvigil 150mg in preoperative area
NUVIGIL: Patient will receive Nuvigil before the surgery</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Placebo in preoperative area</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="12.7"/>
                    <measurement group_id="B2" value="54.7" spread="10.8"/>
                    <measurement group_id="B3" value="53.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Care Unit (PACU) Recovery Time</title>
        <description>Participants will be followed for the duration of PACU stay, an expected average of 3 hours.</description>
        <time_frame>Immediate postoperative period (up to 3 hours)</time_frame>
        <population>Patient with obstructive sleep apnea undergoing surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Nuvigil</title>
            <description>A single oral dose of Nuvigil 150mg in preoperative area
NUVIGIL: Patient will receive Nuvigil before the surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo in preoperative area</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Care Unit (PACU) Recovery Time</title>
          <description>Participants will be followed for the duration of PACU stay, an expected average of 3 hours.</description>
          <population>Patient with obstructive sleep apnea undergoing surgery</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" spread="58.2"/>
                    <measurement group_id="O2" value="95" spread="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Aldrete Score</title>
        <description>Aldrete score used for readiness of PACU discharge by assigning numeric values to the criteria including activity, respiration, circulation, consciousness, and color. Each criterion is rated from 0 to 2, with a maximum score of 10. Scores in the range of 9 to 10 are considered satisfactory for PACU discharge.</description>
        <time_frame>2 hours after extubation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nuvigil</title>
            <description>A single oral dose of Nuvigil at 150mg dose in preoperative area</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single oral placebo will be given in preoperative area
Nuvigil: Patients will receive Nuvigil before the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Aldrete Score</title>
          <description>Aldrete score used for readiness of PACU discharge by assigning numeric values to the criteria including activity, respiration, circulation, consciousness, and color. Each criterion is rated from 0 to 2, with a maximum score of 10. Scores in the range of 9 to 10 are considered satisfactory for PACU discharge.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.27"/>
                    <measurement group_id="O2" value="9.3" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Postoperative 24-h period.</time_frame>
      <desc>Fatigue was assessed during postoperative 24-h period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nuvigil</title>
          <description>A single oral dose of Nuvigil 150 mg in preoperative area
NUVIGIL: Patient will receive Nuvigil before the surgery</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Placebo in preoperative area
Patient will receive placebo before the surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Enas Kandil</name_or_title>
      <organization>University Of Texas Southwestern Medical Center</organization>
      <phone>214-590-8509</phone>
      <email>Enas.Kandil@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

